Who Qualifies for a GLP-1 Medication?

“Who qualifies for a GLP-1 medication?” is one of the most common questions people ask, and the answer is more specific than headlines suggest. The medications used for weight management are prescription drugs with defined labeled uses, and a clinician makes the decision for each person. This guide explains the criteria on the label and what they mean in plain terms. It is general education, not medical advice.

The labeled criteria

For the weight-management versions of semaglutide and tirzepatide, the U.S. Food and Drug Administration approved use in adults, alongside a reduced-calorie diet and more physical activity, who have either:

• A body mass index (BMI) of 30 or higher, which is the range called obesity, or
• A BMI of 27 or higher with at least one weight-related health condition. Examples listed include high blood pressure, high cholesterol (dyslipidemia), type 2 diabetes, obstructive sleep apnea and cardiovascular disease.

The key words are “alongside a reduced-calorie diet and more physical activity.” The label describes the medicine as an addition to lifestyle changes, not a replacement for them.

Labels differ a little between products. For example, one has an approval for adolescents aged 12 and older, and the lists of qualifying conditions are updated from time to time, so the current label is the source to check.

What BMI is, and what it is not

BMI is a simple ratio of weight to height. It is used in the labels because it is easy to measure and standardize, but it is a screening number and not a full picture of health. It does not tell muscle from fat or show where weight is carried. You can work out yours with our BMI calculator, and a clinician will usually consider more than the number.

Who may not be a good fit

Labels also list situations where these medicines should not be used or need extra caution. Examples include:

• A personal or family history of certain thyroid cancers (medullary thyroid carcinoma) or a rare genetic condition called MEN 2, because of a boxed warning about thyroid C-cell tumors seen in animal studies.
• Pregnancy or plans to become pregnant, since weight loss is not recommended in pregnancy.
• History of pancreatitis, gallbladder disease, or kidney problems, which call for closer discussion.
• Allergy to the ingredients.

Our guide to side effects in the big trials covers what participants reported.

Other labeled uses

Some versions have additional approved uses beyond weight management, such as reducing cardiovascular risk in certain adults or treating obstructive sleep apnea in adults with obesity. We cover those in our guides to the SELECT heart trial and to sleep apnea and weight-loss medication. Exact uses and wording can change, so check the current label with your prescriber.

Talking with a clinician

• Bring your full picture. Your history, other medicines, goals and any past weight-loss attempts.
• Ask about expectations. Results vary a lot, as our guide not everyone responds the same way explains.
• Ask about what happens next. Plans for stopping, cost and monitoring, and what we describe in stopping a GLP-1 medication.
• Beware of shortcuts. Our guide to approved versus compounded explains why where a medicine comes from matters.

In short

The label sets a clear starting point, a BMI of 30 or more, or 27 or more with a related condition, and it assumes lifestyle changes continue alongside the medicine. Whether it is right for a particular person is a decision to make with a qualified clinician.

Sources

• U.S. Food and Drug Administration. Prescribing information and drug approval documents for chronic weight management indications (semaglutide and tirzepatide), including clinical review of NDA 217806.
• Medical Letter summaries of the weight-management indications.